Abstracts

Lorenzoni,; Trieste, Leopoldo; Mosca, Marta; Convertino, Irma; Tuccori, Marco; Lucenteforte, E; Ferraro, Sara; Leonardi, Luca; Roberto, Giuseppe; Luciano, N.; Blandizzi, Corrado; Gini, Rosa; Turchetti, Giuseppe

doi:10.1002/pds.4864

Cited by 16 publications

(8 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To minimize the risk of patients being misclassified as PH or PAH patients, we used algorithms that required a composition of procedure, diagnosis, and—for PAH—treatment codes and have been validated using the PheValuator diagnostic predictive modeling tool. 19 , 20 , 21 Such complex algorithms have previously been shown to perform best in terms of specificity and PPV, 20 , 21 minimizing the inclusion of “false positives,” but potentially resulting in conservative estimates of the numbers of PH and PAH patients. Fine‐tuning of the algorithm (e.g., in terms of the definition of time windows) was based on the results of extensive sensitivity analyses and on authors' expertize, which included epidemiology, data science and the clinical input of the authors with medical expertize.…”

Section: Discussionmentioning

confidence: 99%

“…The development of this code‐based definition of PH was based on the findings from a validation study that tested PH algorithms in four different US claims datasets (including the OPTUM claims database used in this study), using PheValuator, a diagnostic predictive modeling tool. 19 , 20 The most complex algorithm in this validation study (a PH diagnosis followed by RHC or TTE and another diagnosis) was used as a basis for the development of the PH algorithm in the present study (with some modifications), as it had the highest specificity and positive predictive value (PPV) of the algorithms tested. The sensitivity, specificity, PPV and negative predictive values (NPV) of our algorithm, as measured using PheValuator, were 49.9%, 99.9%, 79.4%, and 99.8%, respectively, in the OPTUM claims database (50.5%, 99.8%, 79.1%, and 99.3% in the OPTUM EHR database).…”

Section: Methodsmentioning

confidence: 99%

“…The first code for PH diagnosis was used as the date of PH diagnosis. The development of this code‐based definition of PH was based on the findings from a validation study that tested PH algorithms in four different US claims datasets (including the OPTUM claims database used in this study), using PheValuator, a diagnostic predictive modeling tool 19,20 . The most complex algorithm in this validation study (a PH diagnosis followed by RHC or TTE and another diagnosis) was used as a basis for the development of the PH algorithm in the present study (with some modifications), as it had the highest specificity and positive predictive value (PPV) of the algorithms tested.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Time to diagnosis of pulmonary hypertension and diagnostic burden: A retrospective analysis of nationwide US healthcare data

et al. 2023

View full text Add to dashboard Cite

The main aim of this analysis was to investigate time from symptom onset (chronic unexplained dyspnoea [CUD]) to diagnosis of Group 1 pulmonary hypertension (PH)—pulmonary arterial hypertension (PAH)—and to characterize healthcare resource utilization leading up to diagnosis using a nationwide US claims and an electronic health record (EHR) database from Optum © . Eligible patients were ≥18 years old at first CUD diagnosis (index event) and had a PAH diagnosis on or after index date. Based on administrative codes, PAH was defined as right heart catheterization (RHC), ≥ 2 PAH diagnoses (1 within a year of RHC), and ≥1 post‐RHC prescription for PAH treatment. All values are median (1st quartile–3rd quartile) unless otherwise stated. Of 854,722 patients with CUD in the claims database, 582 (0.1%) had PAH. Time from CUD to PAH diagnosis was 2.26 (0.73–4.22) years. PAH patients experienced 3 (2–4) transthoracic echocardiograms (TTEs), 6 (3–12) specialist visits, and 2 (1–4) hospitalizations during the diagnostic interval. Almost one‐third of patients (29%) waited 10 months or more to have a TTE. Findings from the EHR database were broadly similar. Resource utilization during the diagnostic interval was also analyzed in an overall PH cohort: findings were generally similar to the PAH cohort (2 [1–3] TTEs, 4 [2–9] specialist visits and 2 [1–4] hospitalizations). These data indicate a delay in the diagnostic pathway for PAH, and illustrate the burden associated with PAH diagnosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Time to diagnosis of pulmonary hypertension and diagnostic burden: A retrospective analysis of nationwide US healthcare data

et al. 2023

View full text Add to dashboard Cite

show abstract

“…There are several recent projects, such as the Reproducible Evidence: Practices to Enhance and Achieve Transparency (REPEAT) initiative, that aim to improve transparency, reproducibility, and validity of database research [23]. At the same time, the need for one-size-fits-all guidance, or any guidance for protocol development of observational studies, remains a subject of debate [20,21,24,25].…”

Section: Discussionmentioning

confidence: 99%

Standardized Protocol Items Recommendations for Observational Studies (SPIROS) for Observational Study Protocol Reporting Guidelines: Protocol for a Delphi Study (Preprint)

Mahajan¹,

Burza²,

Bouter³

et al. 2020

Preprint

View full text Add to dashboard Cite

BACKGROUND Approximately 90% of currently published clinical and public health research are in the form of observational studies. Having a detailed and registered study protocol prior to data collection is important in any empirical study. Without this, there is no reliable way to assess the occurrence of publication bias, outcome reporting bias and other protocol deviations. However, there is currently no solid guidance available on what information a protocol for an observational study should contain. OBJECTIVE The aim of this study is to formulate the Standardized Protocol Items Recommendations for Observational Studies (SPIROS) reporting guideline, focusing on three main study designs of analytical epidemiology : cohort, case-control, and cross-sectional studies. METHODS A scoping review of published protocol papers of observational studies in epidemiology will be conducted to identify candidate items for the SPIROS reporting guidelines. The list of items will be extended with the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist items and recommendations from the SPIROS steering committee. This long-list serves as the basis for a two-round Delphi survey among experts to obtain consensus on which items to include. Each candidate item from the long-list will be rated on a 5-point Likert scale to assess relevance for inclusion in the SPIROS reporting guideline. Following the Delphi survey, an expert driven consensus workshop will be convened to finalize the reporting guideline. RESULTS A scoping review of published protocol of observational studies has been finished. A total of 59 candidate items for protocols of observational study has been identified .this long of candidate items for the protocols of observational studies will be evaluated by experts. For this purpose, we will conduct a two-round Delphi planned to be launched by February 1st 2020. CONCLUSIONS This project aims to improve the timeliness, completeness and clarity of study protocols of observational studies in analytical epidemiology by producing expert-based recommendations of items to be addressed. This reporting guideline will facilitate and encourage researchers to prepare and register study protocols of sufficient quality, prior to data collection.

show abstract

“…Eleven studies, including those treated as outpatients/OPAT, reported an average length of IV therapy of 2-7 days and an average overall treatment duration of 6-10 days. [59][60][61][62][63][64][65][66][67][68][69] Clinical response rates ranged from 85-97%, failure rates from 5-22% and recurrence rates from 0-6%.…”

Section: Evidence For Overall Duration Of Therapymentioning

confidence: 99%

Route and duration of antibiotic therapy in acute cellulitis: A systematic review and meta-analysis of the effectiveness and harms of antibiotic treatment

Cross

Jordan

Godfrey

et al. 2020

Journal of Infection

View full text Add to dashboard Cite

show abstract

Abstracts

Cited by 16 publications

References 10 publications

Time to diagnosis of pulmonary hypertension and diagnostic burden: A retrospective analysis of nationwide US healthcare data

Time to diagnosis of pulmonary hypertension and diagnostic burden: A retrospective analysis of nationwide US healthcare data

Standardized Protocol Items Recommendations for Observational Studies (SPIROS) for Observational Study Protocol Reporting Guidelines: Protocol for a Delphi Study (Preprint)

Route and duration of antibiotic therapy in acute cellulitis: A systematic review and meta-analysis of the effectiveness and harms of antibiotic treatment

Contact Info

Product

Resources

About